Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 11/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30494215 | 0.74 | LCK (0.70) | ABL1CYP11B1CYP11B2BRAFLCK | |
| SCHEMBL4733367 | 0.74 | LCK (0.70) | ABL1CYP11B1CYP11B2BRAFLCK | |
| SCHEMBL5493001 | 0.74 | ABL1 (0.46) | ABL1CYP11B1CYP11B2BRAFLCK | |
| Ammonia Solution, Strong SCHEMBL5507642 | 0.69 | ABL1 (0.47) | ABL1CYP11B1CYP11B2BRAFLCK | |
| Ammonia Solution, Strong SCHEMBL5496907 | 0.68 | ABL1 (0.62) | ABL1CYP11B1CYP11B2BRAFLCK | |
| SCHEMBL5492999 | 0.67 | ABL1 (0.52) | ABL1CYP11B1CYP11B2BRAFLCK | |
| SCHEMBL5496775 | 0.67 | ABL1 (0.54) | ABL1CYP11B1CYP11B2BRAFLCK | |
| SCHEMBL5495562 | 0.67 | BRAF (0.48) | ABL1CYP11B1CYP11B2BRAFMAP4K1 | |
| SCHEMBL5503011 | 0.66 | BRAF (0.43) | ABL1BRAFLCKKDRJAK3 | |
| SCHEMBL14569081 | 0.65 | ABL1 (0.58) | ABL1BRAFLCKKDRJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836174-B2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2019-10-02 | — | — | EP | claimed |
| EP-1836174-B1 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2013-02-27 | — | — | EP | claimed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | MAP3K1, MAP3K5, MAP3K2 | ABL1 32/4885CYP11B1 154/4885CYP11B2 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.